Table 3.

Relationship between a history of migraine and risks of invasive ductal and invasive lobular breast carcinomas by joint ER/PR status

Ductal carcinoma
Controls (n = 1,474)
ER+/PR+ (n = 855)
ER+/PR (n = 133)
ER/PR (n = 147)
n (%)n (%)OR* (95% CI)n (%)OR* (95% CI)n (%)OR* (95% CI)
Never diagnosed with migraine1,202 (82)739 (87)1.00 (reference)120 (90)1.00 (reference)121 (82)1.00 (reference)
Ever diagnosed with migraine272 (19)114 (13)0.65 (0.51-0.83)13 (10)0.49 (0.27-0.88)26 (18)0.87 (0.56-1.36)
Age at migraine diagnosis (y)
    <2073 (5)26 (3)0.56 (0.35-0.88)2 (2)0.28 (0.07-1.16)3 (2.0)0.37 (0.11-1.19)
    20-39110 (8)57 (7)0.82 (0.59-1.15)6 (5)0.56 (0.24-1.30)15 (10)1.24 (0.70-2.21)
    ≥4089 (6)31 (4)0.53 (0.35-0.81)5 (4)0.57 (0.23-1.44)8 (5)0.82 (0.39-1.74)
    P value for difference across age categories0.800.430.37
Ever use of prescription migraine medications
    No127 (9)47 (6)0.56 (0.39-0.79)6 (5)0.48 (0.21-1.11)11 (8)0.79 (0.41-1.51)
    Yes144 (10)65 (8)0.72 (0.53-0.98)6 (5)0.43 (0.19-1.00)15 (10)0.95 (0.54-1.67)
    P value for difference across medication categories0.270.850.66
Lobular carcinoma
Controls (n = 1,474)
ER+/PR+ (n = 560)
ER+/PR (n = 110)
n (%)
n (%)
OR* (95% CI)
n (%)
OR* (95% CI)
Never diagnosed with migraine1,202 (82)481 (86)1.00 (reference)92 (84)1.00 (reference)
Ever diagnosed with migraine272 (19)78 (14)0.63 (0.47-0.85)18 (16)0.80 (0.47-1.36)
Age at migraine diagnosis (y)
    <2073 (5)19 (4)0.59 (0.34-1.03)3 (3)0.50 (0.15-1.65)
    20-39110 (8)34 (7)0.73 (0.47-1.13)6 (6)0.70 (0.30-1.66)
    ≥4089 (6)23 (5)0.50 (0.30-0.82)9 (8)1.10 (0.53-2.29)
    P value for difference across age categories0.600.20
Ever use of prescription migraine medications
    No127 (5)35 (6)0.57 (0.38-0.86)10 (9)0.91 (0.46-1.81)
    Yes144 (10)42 (8)0.68 (0.46-1.00)8 (7)0.70 (0.33-1.49)
    P value for difference across medication categories0.530.60
  • * ORs adjusted for age and reference year.

  • P < 0.05.